<DOC>
	<DOCNO>NCT01651936</DOCNO>
	<brief_summary>The purpose study assess safety efficacy MK-8457 + Methotrexate ( MTX ) participant active rheumatoid arthritis ( RA ) inadequate response intolerance anti-tumor necrosis factor α ( anti-TNF-α ) therapy . The primary hypothesis study among participant active RA , MK-8457 100 mg twice daily ( BID ) + MTX superior placebo + MTX measure change Disease Activity Score 28 C-Reactive Protein ( DAS28-CRP ) 12 week treatment .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Placebo-Controlled , Parallel-Group , Multicenter Trial Evaluate Safety , Tolerability , Efficacy MK-8457 Participants With Rheumatoid Arthritis ( MK-8457-010 )</brief_title>
	<detailed_description>In Base Study , participant receive blind MK-8457 100 mg + MTX match placebo + MTX 24 week . At Week 12 18 , efficacy evaluation conduct assess eligibility early escape , define &lt; 20 % improvement tender swell joint count . Participants complete Base Study eligible early escape could enroll 76-week Safety Extension participant receive open-label MK-8457 100 mg BID + MTX . All participant must treat MTX least 3 month prior Screening receive stable dose MTX least 4 week prior Screening . In addition , participant must either fail treatment 1 2 anti-TNF-α therapy intolerant anti-TNF-α therapy prior Screening . For participant fail therapy , treatment anti-TNF-α therapy must least 3 month .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Diagnosis rheumatoid arthritis least 6 month prior screen Active rheumatoid arthritis define presence &gt; = 6 swollen joint ( 66 count ) &gt; = 6 tender joint ( 68 joint count ) Creactive protein blood level &gt; 0.9 mg/dL elevate erythrocyte sedimentation rate ( ESR ) &gt; 28 mm/hr evidence synovitis image American College Rheumatology Functional Class I , II , III Received methotrexate minimum 3 month prior screen regionally appropriate stable weekly dose least 4 week prior screen . The dose methotrexate must remain stable Week 24 study . Failed treatment 1 2 antitumor necrosis factor alpha ( antiTNFα ) therapies intolerant antiTNFα therapy prior screen If use nonsteroidal antiinflammatory drug analgesic , participant must stable dose No history either untreated latent active tuberculosis ( TB ) prior baseline Participants reproductive potential must agree remain abstinent use 2 acceptable method birth control Presence inflammatory disease rheumatoid arthritis , include limited psoriatic arthritis , ankylose spondylitis , systemic lupus erythematosus , Lyme disease Hospitalization due acute cardiovascular event , cardiovascular illness , cardiovascular surgery within 6 month screen Participant transplant organ , exclude corneal transplant , perform &gt; 3 month prior first dose trial medication History , current ongoing , chronic recurrent infectious disease Positive hepatitis B surface antigen hepatitis C test result Human immunodeficiency virus ( HIV ) positive User recreational illicit drug history ( within previous 2 year ) drug alcohol abuse dependence Prior exposure fostamatinib spleen tyrosine kinase inhibitor Prior exposure 3 antiTNF therapeutic agent Has treat RA market biologic agent ( antiTNF therapeutic agent ) fail agent due lack efficacy Currently participate another interventional clinical trial participate interventional clinical trial within 4 week prior screen Severe opportunistic infection within 6 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>